MCM
IRD

MAI Capital Management’s Opus Genetics IRD Stock Holding History

MAI Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-123
Closed -$203 – 4505
2025
Q3 		$203 Hold
123
– – ﹤0.01% 3711
2025
Q2 		$116 Hold
123
– – ﹤0.01% 3891
2025
Q1 		$121 Sell
123
-876
-88% -$979 ﹤0.01% 3347
2024
Q4 		$1.19K Buy
+999
New +$1.15K ﹤0.01% 3155
2024
Q2 		– Sell
-223,970
Closed -$450K – 1301
2024
Q1 		$450K Sell
223,970
-167,926
-43% -$426K ﹤0.01% 842
2023
Q4 		$1.18M Sell
391,896
-63,781
-14% -$189K 0.02% 430
2023
Q3 		$1.53M Sell
455,677
-29,371
-6% -$118K 0.02% 349
2023
Q2 		$2.11M Sell
485,048
-9,642
-2% -$45.8K 0.03% 292
2023
Q1 		$1.86M Buy
494,690
+54,619
+12% +$196K 0.03% 305
2022
Q4 		$1.55M Buy
440,071
+83,123
+23% +$219K 0.03% 331
2022
Q3 		$717K Buy
+356,948
New +$770K 0.01% 452

Other funds holding IRD

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

MAI Capital Management's IRD Position: Q4 2025 in Review

MAI Capital Management sold out of Opus Genetics (IRD) in Q4 2025, closing a stake of 123 shares — an estimated $203 sold.

MAI Capital Management first reported a position in IRD in Q3 2022 and held it in 11 quarters. The position peaked at $2.11M in Q2 2023. 59 funds tracked by Wall St. Rank hold IRD as of Q4 2025.

  • MAI Capital Management reported no remaining Opus Genetics position as of Q4 2025 after selling out during the quarter.
  • MAI Capital Management sold 123 Opus Genetics shares in Q4 2025, an estimated $203.
  • MAI Capital Management first reported a position in Opus Genetics in Q3 2022 and held it in 11 quarters.
  • MAI Capital Management's Opus Genetics position peaked at $2.11M in Q2 2023.
  • 59 funds tracked by Wall St. Rank held Opus Genetics as of Q4 2025.

Based on MAI Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.